RxDoctor Payments DataLook up a doctor →

Andrew Khoury, MD

Pain Medicine · The Woodlands, TXNPI 1164840534

Payments from drug & device makers

$83,148in general payments, 2019–2025

Across 599 payments — averaging $138.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik NRO, Inc.$20K
  • Interventional Pain Technologies Inc.$14K
  • Medtronic$14K
  • Abbott$10K
  • Spinal Simplicity, LLC$10K
  • Globus Medical$4K
  • plus $11K from 37 others

What the payments were for

  • Consulting fees$18,68924%
  • Speaking & faculty fees$20,56826%
  • Travel & lodging$15,17819%
  • Food & beverage$18,45423%
  • Education$6,0008%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,148 in reported general payments places this provider in the 95th percentile of 583 pain medicine providers in Texas.

See all pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$520,040
Medicare patients
331
Services billed
13,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl41$32,644
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen836$21,779
Buprenorphine23$5,882
Xtampza ErOxycodone Myristate12$5,212
Lidocaine51$5,159
Gabapentin270$3,331
Fentanyl11$3,166
Pregabalin95$3,140
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen159$2,927
Diclofenac Sodium117$1,994
Metaxalone12$1,719
Tramadol Hcl76$1,539
Tizanidine Hcl148$1,459
Tramadol Hcl ErTramadol Hcl14$1,150
Methocarbamol80$977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$95$37,85653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 pain medicine providers in Texas.

Other pain medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →